Up-Regulation of the Receptor for Advanced Glycation End Products in the Skin Biopsy Specimens of Patients with Severe Diabetic Neuropathy

Su-Yeon Park,* a Young-A Kim,* b Yoon-Ho Hong, c Min-Kyong Moon, d Bo-Kyeong Koo, d Tae Wan Kim e

a Department of Neurology, Korea Cancer Center Hospital, Seoul, Korea
b Departments of Pathology, c Neurology, d Endocrinology and Metabolism, and e Ophthalmology, Seoul Metropolitan Government Boramae Medical Center, Seoul National University College of Medicine, Seoul, Korea

Received August 9, 2013
Revised February 17, 2014
Accepted February 17, 2014

Correspondence
Yoon-Ho Hong, MD, PhD
Department of Neurology, Seoul Metropolitan Government Boramae Medical Center, Seoul National University College of Medicine, 20 Boramae-ro 5-gil, Dongjak-gu, Seoul 156-707, Korea
Tel +82-2-840-2474
Fax +82-2-3672-7553
E-mail nrhong@gmail.com

*These two authors contributed equally to this article.

Background and Purpose The receptor for advanced glycation end products (RAGE) may contribute to the development of diabetic neuropathy. To assess its relevance in humans, this study examined the expression of RAGE in the skin biopsy samples of patients with diabetes mellitus, and investigated its correlation with intraepidermal nerve-fiber density (IENFD) and clinical measures of neuropathy severity.

Methods Forty-four patients who either had type 2 diabetes or were prediabetes underwent clinical evaluation and a 3-mm skin punch biopsy. The clinical severity of their neuropathy was assessed using the Michigan Diabetic Neuropathy Score. IENFD was measured along with immunohistochemical staining for RAGE in 29 skin biopsy samples. The expression of RAGE was also quantified by real-time reverse-transcription PCR in the remaining 15 patients.

Results RAGE was localized mostly in the dermal and subcutaneous vascular endothelia. The staining was more intense in patients with a lower IENFD (p=0.004). The quantity of RAGE mRNA was significantly higher in patients with severe neuropathy than in those with no or mild neuropathy (p=0.003). The up-regulation of RAGE was related to dyslipidemia and diabetic nephropathy. There was a trend toward decreased sural nerve action-potential amplitude and slowed peroneal motor-nerve conduction with increasing RAGE expression.

Conclusions The findings of this study demonstrate up-regulation of RAGE in skin biopsy samples from patients with diabetic neuropathy, supporting a pathogenic role of RAGE in the development of diabetic neuropathy.

Key Words receptor for advanced glycation end products, diabetes mellitus, diabetic neuropathy.

Introduction

Diabetic neuropathy is a common complication of diabetes mellitus, typically manifesting as chronic symmetric length-dependent sensorimotor axonal polyneuropathy.1 It can cause significant functional impairment and disability in diabetic patients, leading to a reduced quality of life as well as considerable costs for health care.2 There is no specific disease-modifying therapy, and the exact pathogenesis and molecular mechanisms remain elusive.3-5 Skin punch biopsy and quantification of intraepidermal nerve-fiber density (IENFD) have recently emerged as an early surrogate marker of both diabetic neuropathy and small-fiber neuropathy.6-9 IENFD is negatively associated with the duration of diabetes and with neuropathic deficits,10,11 and is significantly reduced in patients even at the early stage of diabetic neuropathy when nerve conduction is normal.5,12
Advanced glycation end products (AGE) and their receptors (RAGE) are of particular interest with respect to their potential contribution to development of microvascular complications of diabetes.\textsuperscript{13,14} AGEs result from the nonenzymatic glycation of proteins, lipids, and nucleotides, and chronic hyperglycemia in diabetes enhances their formation and accumulation causing possibly detrimental structural and functional modifications of macromolecules.\textsuperscript{13} AGEs also trigger intracellular signaling pathways by binding to one of their cell-surface receptors, RAGE, leading to the activation of nuclear factor kappa B (NF-κB) and nicotinamide adenine dinucleotide phosphate (NADPH) oxidases, which ultimately increases the levels of oxidative stress and inflammation.\textsuperscript{16-19}

Recent studies have implicated the activation of RAGE as a possible mechanism of diabetic neuropathy.\textsuperscript{13,17,20} The expression of RAGE was found to increase in the peripheral nervous system of experimental animal models of diabetic neuropathy.\textsuperscript{13,17,20} Deletion of RAGE was found to protect mice from diabetic neuropathy, while its overexpression promoted diabetic neuropathy.\textsuperscript{13,17,19,20} In addition, loss of pain perception and the structural changes of neuropathy were largely prevented in RAGE-knockout mice.\textsuperscript{17,20}\textsuperscript{18-19} However, the relevance of RAGE expression, particularly in terms of small-fiber loss, has not been investigated in human diabetic neuropathy. The aim of this study was to determine the association between RAGE expression in the skin and IENFD by examining the expression of RAGE using immunohistochemistry and real-time reverse-transcription (RT) PCR (RT-PCR). We also analyzed the correlations between RAGE expression and the overall clinical severity of diabetic neuropathy, large-fiber pathology measured by nerve conduction studies, metabolic status, and markers of the microvascular complications of diabetes.

**Methods**

**Patients**

Forty-four patients who either had type 2 diabetes or were pre-diabetes (impaired fasting glucose or impaired glucose tolerance) as diagnosed according to the American Diabetes Association Clinical Practice Recommendations were included in this study, and all were recruited at the Seoul Metropolitan Government Boramae Medical Center between June 2010 and March 2011.\textsuperscript{21} The exclusion criteria included a history of inherited neuropathy, toxin exposure, any medical conditions including thyroid disease, nutritional deficiency, renal disease, and patients on medications with the potential for causing peripheral neuropathy such as chemotherapy drugs or tuberculosis treatment. All patients underwent a clinical evaluation that comprising a detailed neurological examination and laboratory tests that included fasting blood glucose, oral glucose tolerance test, hemoglobin A1c (HbA1c), lipids, thyroid function test, and vitamin B12. The degree of albuminuria was assessed, and diabetic retinopathy was graded into the following five categories: none, mild, moderate, severe nonproliferative retinopathy, and proliferative diabetic retinopathy.\textsuperscript{22} Written informed consent to participate was obtained from all patients, and the study was approved by the Institutional Review Board of Seoul Metropolitan Government Boramae Medical Center. The clinical severity of diabetic neuropathy was evaluated using the Michigan Diabetic Neuropathy Score, and the patients were categorized into four groups (none, mild, moderate, and severe neuropathy) based on the neurological examination and electrophysiological test results.\textsuperscript{21} The typical chronic, symmetric, length-dependent sensorimotor axonal polyneuropathy was the only variety of diabetic neuropathy in our study. Patients with diabetic neuropathy of focal/multifocal varieties or with demyelinating features were excluded, as were those with a generalized, but atypical polyneuropathy in terms of mode of onset and course.

**Skin biopsy: IENFD and immunohistochemical staining for RAGE**

Intraepidermal nerve-fiber density was measured, and the expression of RAGE was assessed by immunohistochemical staining of the skin biopsy samples from 29 patients. A skin sample was obtained by a 3-mm punch biopsy from the distal leg (10 cm above the lateral malleolus) from each of the selected patients after applying lidocaine for topical anesthesia.\textsuperscript{18} The biopsied skin was immediately fixed with 2% paraformaldehyde-lysine-periodate for 12–24 hours, and cryoprotected at 4°C. Half of the skin samples were sectioned at a thickness of 50 µm using a freezing sliding microtome, and the other half were reserved for immunohistochemical staining of RAGE. The 50-µm-thick skin sections were stained with polyclonal rabbit antihuman protein gene product 9.5 (PGP9.5) antibody (diluted 1:1,200; Chemicon, Billerica, MA, USA). The PGP9.5-immunoreactive intraepidermal nerve fibers were counted under a light microscope at a magnification of ×400; only those fibers crossing the dermal-epidermal junction were counted. The mean value of IENFD was derived from at least three sections and expressed as the fiber count per unit length.

The reserved skin specimens were thawed, washed three times with phosphate buffered saline, fixed in 10% neutral formalin, and then embedded in paraffin. Formalin-fixed paraffin-embedded skin samples were then sectioned and subjected to immunohistochemical staining for RAGE. The tissues were stained with monoclonal mouse antihuman RAGE antibody (diluted 1:200; Santa-Cruz Biotechnology, Santa-Cruz, CA, USA), and the staining intensity was graded.
from I to IV as follows: grade I, absence of staining; grade II, faint staining (only visible under high power); grade III, moderate staining (easily visible under low power); and grade IV, intense staining. The examiner (Y. Kim) was blinded to the identity of the specimens.

**Real-time RT-PCR**

Total RNA was extracted, isolated, and purified from a frozen sample of each 3-mm skin punch biopsy specimen from 15 patients using the homogenizer extraction technique with a commercially available kit (RNeasy Mini Kit, Qiagen, Valencia, CA, USA). The RNA quantity and quality were assessed by UV spectroscopy (NanoDrop ND-1000, NanoDrop Technologies Inc., Wilmington, DE, USA), which assessed the ratio of the absorbances at 260 nm and 280 nm. The integrity of the total RNA was quantified by electrophoresis on a denaturing agarose gel with ethidium bromide. Reverse transcription using dissolved RNA in diethylpyrocarbonate-treated water was performed using a GeneAmp EZ rTth RNA PCR kit (Perkin Elmer) at 60°C for 30 min. The real-time RT-PCR was carried using the LightCycler system (Roche Diagnostics, Basel, Switzerland) with SYBR Green as the fluorescent dye. The 18S ribosomal RNA was used as an internal control gene. The complementary DNA samples were amplified with specific primers. The RAGE primer sequences were as follows: forward, 5'-GGAAAGGAGACCAAGTCCAA-3'; backward, 5'-CATCCAGTGCCAGCTAAGA-3'. The glyceraldehyde 3-phosphate dehydrogenase (GAPDH) sequences were as follows: forward, 5'-CAATGCCCCCTTCAATGACC-3'; backward, 5'-TGGACTCCACGACTAATCA-3'. The relative quantification method 2-ΔΔCT was applied to detect changes in target samples relative to an internal control in the analysis of the quantitative real-time RT-PCR. The total quantity of RAGE messenger RNA (mRNA) was assessed by threshold cycle for amplification of the target gene, and GAPDH was used as an internal control gene. The amplification efficiencies of both the target and control genes were almost the same (close to 2), validating the calculation method. The amount of RAGE mRNA relative to GAPDH was determined for each sample and divided by the ratio (RAGE/GAPDH) of a calibrator tissue (lung in the present study) to normalize all samples within and between runs. Statistical analysis

Correlations were analyzed using Spearman correlation analysis. The Kruskal-Wallis test was used in comparisons involving more than two groups. Fisher’s exact test was performed for categorical variables. The cutoff for statistical significance was set at p<0.05. Statistical tests were performed using R.

**Table 1. Clinical characteristics of patients categorized according to the clinical severity of their diabetic neuropathy**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Michigan Diabetic Neuropathy Staging</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>No 61.5 (52.8–68.0) Mild 61.0 (53.0–71.0) Moderate 61.0 (55.8–67.3) Severe 61.0 (48.0–70.0) 0.967</td>
<td></td>
</tr>
<tr>
<td>Sex (women:men)</td>
<td>3:3 7:8 4:6 6:7 0.981</td>
<td></td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>23.0 (21.6–24.2) 24.2 (20.8–27.7) 26.4 (21.2–27.6) 24.3 (21.9–27.3) 0.683</td>
<td></td>
</tr>
<tr>
<td>Duration of DM (years)</td>
<td>10.0 (4.8–13.3) 8.0 (3.0–17.0) 9.0 (5.5–12.0) 11.0 (8.0–15.5) 0.661</td>
<td></td>
</tr>
<tr>
<td>Treatment</td>
<td>5:0:0 1:8:6 1:4:5 3:5:5 0.139</td>
<td></td>
</tr>
<tr>
<td>[OMA:insulin:OMA+insulin]</td>
<td>FBS (mg/dL) 154 (131.5–208.5) 124.0 (118.0–131.0) 123.0 (108.5–143.5) 134.0 (115.5–174.5) 0.229 193 (164.3–341.0) 224.0 (147.0–277.0) 191.0 (174.0–296.0) 278.0 (217.0–348.8) 0.396</td>
<td></td>
</tr>
<tr>
<td>Postprandial 2-hour plasma glucose (mg/dL)</td>
<td>7.2 (6.8–7.7) 7.3 (6.4–8.8) 6.9 (6.5–7.3) 8.6 (6.9–9.6) 0.410</td>
<td></td>
</tr>
<tr>
<td>HbA1c (% mmol/mol)</td>
<td>54.5 (50.5–59.8) 56.0 (46–73) 52.0 (47.5–56.5) 70.0 (51.5–80.5) 0.331</td>
<td></td>
</tr>
<tr>
<td>eGFR (MDRD, mL/min/1.7 m²)</td>
<td>89.3 (75.4–107.7) 76.8 (66.6–97.9) 87.2 (77.8–97.4) 77.2 (45.2–84.4) 0.331</td>
<td></td>
</tr>
<tr>
<td>Microalbumin (mg/24 hours)</td>
<td>18.3 (10.3–26.5) 8.3 (4.8–48.3) 12.4 (4.5–22.2) 98.5 (177.7–1614.7) 0.027*</td>
<td></td>
</tr>
<tr>
<td>Diabetic retinopathy (none: mild/moderate:severe NPDR: PDR)</td>
<td>Total cholesterol (mg/dL) 176.5 (111.3–210.3) 141.0 (111.0–169.0) 142.5 (121.8–175.3) 155.0 (142.0–193.5) 0.370</td>
<td></td>
</tr>
<tr>
<td>LDL cholesterol (mg/dL) 98.5 (58.0–130.5) 88.0 (56.3–103.3) 80.5 (73.3–111.0) 82.0 (72.0–111.0) 0.767</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Triglyceride (mg/dL) 156.5 (112.3–228.0) 143.0 (84.0–206.5) 87.0 (64.8–151.5) 138.0 (109.0–202.0) 0.240</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HDL cholesterol (mg/dL) 39.0 (31.0–54.3) 43.0 (36.5–50.3) 40.0 (29.5–59.3) 41.0 (36.5–57.5) 0.744</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

All continuous data are expressed as median (interquartile range) values.
*Significantly different at p<0.05.
Results

The clinical characteristics of the patients are summarized in Table 1, and the results of clinical and histological measures of diabetic neuropathy are given in Table 2. The patients with a greater severity of diabetic neuropathy had a significantly lower IENFD ($p<0.001$) (Table 2, Fig. 1A). We also found a significant correlation between the Michigan Diabetic Neuropathy Score and IENFD ($\rho=-0.76, p<0.0001$) (Fig. 1B). Immunohistochemical staining revealed that RAGE was localized almost exclusively in the dermal and subcutaneous vascular endothelia, with only slight expression in the basal cells of the epidermis (Fig. 2). The patients with a greater severity of diabetic neuropathy exhibited a higher grading in RAGE immunohistochemical staining ($p=0.028$) (Table 2).

As illustrated in Fig. 3, IENFD was also significantly lower in patients with a higher intensity of RAGE staining: the median (interquartile range) IENFD values were 6.7 (5.3–8.5),

<table>
<thead>
<tr>
<th>Michigan Diabetic Neuropathy Staging</th>
<th>No</th>
<th>Mild</th>
<th>Moderate</th>
<th>Severe</th>
<th>$p$</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of patients</td>
<td>4</td>
<td>8</td>
<td>10</td>
<td>7</td>
<td></td>
</tr>
<tr>
<td>Michigan Diabetic Neuropathy Score</td>
<td>1 (0–2.5)</td>
<td>9 (8–12.5)</td>
<td>20 (18.5–20)</td>
<td>28 (27–32)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>IENFD [mm$^{-1}$]</td>
<td>8.9 (8.1–10.6)</td>
<td>5.4 (4.7–6.0)</td>
<td>2.2 (1.8–2.9)</td>
<td>1.9 (1.4–2.2)</td>
<td>0.00017</td>
</tr>
<tr>
<td>RAGE immunostaining grade (no. of patients)</td>
<td>2</td>
<td>4</td>
<td>1</td>
<td>0</td>
<td>0.028</td>
</tr>
</tbody>
</table>

All continuous data are expressed as median (interquartile range) values.

IENFD: intraepidermal nerve-fiber density, RAGE: receptors for advanced glycation end products.

Fig. 1. Intraepidermal nerve-fiber density (IENFD) in skin biopsy specimens of patients with different clinical severities of diabetic neuropathy. A: Kruskal-Wallis rank sum test, $p=0.00017$. B: Spearman correlation analysis, $\rho=-0.76, p<0.0001$.

Fig. 2. Immunohistochemical staining ($\times200$) for receptor for advanced glycation end products (RAGE) in the vascular endothelium (arrowheads) of the superficial dermis (A), deep dermis (B), and subcutaneous region (C) in a patient with severe diabetic neuropathy. Basal cells in the epidermis are marginally stained for RAGE, although it is difficult to distinguish between the melatonin in those cells and the immunoreactivity (A).
Upregulation of RAGE in Diabetic Neuropathy

4.2 (2.3–6.7), 1.9 (1.7–2.0), and 2.3 (0.8–2.9) per mm² for grades I, II, III, and IV of RAGE immunostaining, respectively (p=0.0037) (Fig. 3). Furthermore, the quantity of mRNA as measured by real-time RT-PCR was significantly higher in patients with severe neuropathy than in those with no or mild neuropathy (p=0.0028); the median relative change relative to GAPDH was 1.06×10⁻³ (range, 0.51×10⁻³ to 0.42×10⁻³) and 5.46 (range, 1.35×10⁻³ to 0.11) in the group with no and mild neuropathy combined (n=9) and the group with severe neuropathy (n=6), respectively.

The relevance of RAGE expression in terms of nerve-conduction abnormalities was also analyzed; the results are illustrated in Fig. 4. The sural sensory-nerve action potential (SNAP) amplitude and peroneal motor-nerve conduction velocity (MNCV) were the two key electrophysiological parameters used, which are well known to be correlated with characteristic structural lesions of myelinated fibers. These nerve-conduction parameters did not differ significantly between the RAGE-immunostaining groups (Kruskal-Wallis rank sum test: p=0.32 for sural SNAP amplitude and p=0.63 for peroneal MNCV). Furthermore, the correlations between these nerve-conduction parameters and RAGE mRNA expression were not significant (Spearman analysis: p=0.19 for sural SNAP amplitude and p=0.07 for peroneal MNCV). However, despite

Fig. 3. Intraepidermal nerve-fiber density (IENFD) in skin biopsy specimens of patients with different levels of immunostaining for receptor for advanced glycation end products (RAGE); Kruskal-Wallis rank sum test, p=0.0037 (A). Relative change in RAGE mRNA (relative to glyceraldehyde 3-phosphate dehydrogenase), normalized to the expression in the lung (calibrator tissue), as quantified by real-time reverse-transcription PCR (B). Each bar represents the result for an individual patient. The mean and upper (lower) errors were determined from triplicates of each sample. Wilcoxon rank sum test for comparison of severe vs. no or mild neuropathy, p=0.0028.

Fig. 4. Relationships between receptor for advanced glycation end products (RAGE) expression and nerve-conduction parameters. Sural sensory-nerve action potential (SNAP) amplitudes (A and B), and peroneal motor-nerve conduction velocities (MNCVs) (C and D). RAGE immunohistochemical staining (A and C), and RAGE reverse-transcription-PCR (B and D).
this lack of statistical significance there was a definite trend toward decreased sural SNAP amplitudes and slowed peroneal MNCVs with increasing RAGE expression.

We also examined the correlations between RAGE expression and various metabolic and vascular parameters of diabetic neuropathy; the results are illustrated in Supplementary Fig. 1. Serum triglyceride was significantly higher in groups with mild-to-moderate levels of RAGE immunostaining (Kruskal-Wallis test, $p=0.0043$). There were also significant correlations between serum cholesterol [total and low-density lipoprotein (LDL)] and RAGE mRNA expression (Spearman analysis: $\rho=0.64$ and $p=0.028$ for total cholesterol, and $\rho=0.76$ and $p=0.007$ for LDL). However, we found no significant correlations for other metabolic parameters including fasting and postprandial 2-hour plasma glucose and HbA1c. As for the markers of microvascular complications of diabetes, the up-regulation of RAGE was correlated with a lower estimated glomerular filtration rate (eGFR) and increased 24-hour urine albumin, although these correlations had marginal significance (Spearman analysis: $\rho=0.51$ and $p=0.09$ for eGFR, and $\rho=0.62$ and $p=0.06$ for 24-hour urine albumin). The severity of diabetic retinopathy was not significantly associated with the level of RAGE expression.

**Discussion**

The present study found that RAGE immunoreactivity was localized mostly in the dermal and epidermal vascular endothelia. The staining was more intensity in patients with a lower IENFD. We further measured RAGE gene expression, and found that patients with severe neuropathy had higher levels of RAGE mRNA. The relevance of RAGE expression specifically in terms of large-myelinated-fiber pathology was also suggested by the finding of decreased sural SNAP amplitudes and slowed peroneal MNCVs with increasing RAGE, although the statistics did not reach significance. The level of RAGE mRNA was also found to be correlated with markers of diabetic nephropathy. In addition, the up-regulation of RAGE was related to dyslipidemia, which supports an emerging concept that dyslipidemia may play an important role in the progression of diabetic neuropathy. 

Receptor for advanced glycation end products is known to be expressed in various types of cell. RAGE expression has been demonstrated in the endothelial cells of perineural and endoneurial tissues, epidermal and sural axons, Schwann cells, and dorsal root ganglia sensory neurons in various experimental models of diabetic neuropathy. In sural nerve tissue biopsied from patients with diabetic neuropathy, RAGE was localized in the microvasculature of the peripheral nerve along with activation of NF-κB and protein kinase C pathways. RAGE blockade with soluble RAGE or knockout was reported to limit activation of these signaling pathways, and to attenuate the features of neuropathy.

Receptor for advanced glycation end products is known to be expressed in various types of cell. RAGE expression has been demonstrated in the endothelial cells of perineural and endoneurial tissues, epidermal and sural axons, Schwann cells, and dorsal root ganglia sensory neurons in various experimental models of diabetic neuropathy. In sural nerve tissue biopsied from patients with diabetic neuropathy, RAGE was localized in the microvasculature of the peripheral nerve along with activation of NF-κB and protein kinase C pathways. RAGE blockade with soluble RAGE or knockout was reported to limit activation of these signaling pathways, and to attenuate the features of neuropathy.

The potential utility of skin biopsy sampling and analysis could be extended beyond the quantification of IENFD and morphometric analysis. The skin biopsy could be used to determine molecular signatures that may be specific to peripheral neuropathies of various etiologies. RAGE in this study could be a representative example. Recent technical advances in RNA extraction from very small samples makes it possible to apply more sophisticated techniques for high-throughput gene-expression analysis. The results of the present study show that quantification of mRNA is feasible even for molecules that are expressed as weakly as RAGE in the skin.

While the number of patients in the present study was too small to enable us to draw robust conclusions, our findings suggest an association between RAGE up-regulation mainly in the vascular endothelial cells of the skin and both the small- and large-fiber components of diabetic neuropathy. These results should be confirmed in a larger study. It would also be interesting to investigate whether the up-regulation of RAGE observed in the present study is specific to diabetic
Upregulation of RAGE in Diabetic Neuropathy

Conflicts of Interest
The authors have no financial conflicts of interest.

Acknowledgements
This study was supported by a grant from the Korea Healthcare Technology R&D Project, Ministry for Health, Welfare and Family Affairs, Republic of Korea (A090592), a grant no 04-2010-0250 from the Seoul National University Hospital Research Fund, and a clinical research grant-in-aid from the Seoul Metropolitan Government Seoul National University Boramae Medical Center (03-2007-7).

REFERENCES


